Fortune 40: Best stocks to retire on
Our trademark long-term portfolio can help put you on the road to a secure future.
GROWTH AND INCOME: Abbott Labs
Market cap (billions): $83.6
P/E ratio*: 19
Earnings growth**: 11%
Dividend yield: 2.6%
Abbott Laboratories, the fourth-largest drugmaker in terms of annual sales, has had tremendous success with fast-growing drugs like Humira, an anti-inflammatory, and Kaletra, an HIV treatment. Earnings in its last quarter surged 35%.
Despite the success of its pharmaceutical division, CEO Miles White is determined to keep focusing on the company's medical devices branch, which has emerged as a leader in drug-coated stents. White thinks this approach will help Abbott weather the regulatory and patent-related stumbling blocks that are hitting its pure pharma rivals.
NEXT: GROWTH AND INCOME: Coca-Cola
-
Abbott Labs -
Coca-Cola -
Colgate-P... -
General M... -
Illinois ... -
Johnson &... -
Procter &... -
US Bancorp -
Accenture -
Chubb -
Cisco Sys... -
McKesson -
3M -
Microsoft -
Parker Ha... -
Walgreen -
Applied I... -
Carlisle ... -
Cascade -
National ... -
Pfizer -
Regal Bel... -
UST -
VF Corp. -
Adtran -
AVX -
Fair Isaac -
Global In... -
Grey Wolf -
Penn Virg... -
Plexus -
Tessera T... -
BP -
Diageo -
Novartis -
Philips E... -
Sanofi-Av... -
Total -
Unilever -
Vodafone ...
Last updated June 20 2008: 2:35 PM ET
RSS Criteria include long-term earnings growth equal to or greater than the S&P 500's estimated 7% rate, dividend yield greater than the S&P 500's 2%, and P/E ratios below 27.
*Based on previous 12-months' reported earnings.
**Wall Street estimates for the next three to five years.
Source: Zacks Investment Research
*Based on previous 12-months' reported earnings.
**Wall Street estimates for the next three to five years.
Source: Zacks Investment Research
